FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...

FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the ...

FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2025 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company, which makes devices ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on the ...

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell ...

Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective reduced by Morgan Stanley from $9.00 to $7.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an ...